JerrySoto700 Posted - 5 days ago

$BIO AITX's progress highlights the importance of overcoming KSCP's current challenges to stay competitive.

DebWater_ Posted - 2 weeks ago

$CKPT $BIO $SPY $QQQ Today is a HUGE, HUGE Day today in the USA. Everyone has a right to their own opinion on who they want to win, I get that. But for me personally. TRUMP needs to WIN!! Lets Do This DONALD J. TRUMP!!!! Hoping $CKPT has a Great Green Day today.

Powerbattles Posted - 2 weeks ago

$BIO WOW! $2.80

Shlobby Posted - 10/31/24

$BIO nice candle today. Forming a bottom here

IN0V8 Posted - 10/31/24

$BIO Citigroup raises target price to $450 from $400 RBC raises target price to $469 from $446 UBS cuts target price to $390 from $400

DonCorleone77 Posted - 10/30/24

$BIO Bio-Rad sees non-GAAP revenue down 2.5%-4% for FY24 Bio-Rad continues to expect its non-GAAP revenue to decline by approximately 2.5 to 4.0 percent on a currency-neutral basis. The company estimates a non-GAAP operating margin of between 12.75 to 13.25 percent, which now also includes the impact of a one-time acquired in-process research and development expense related to an acquisition completed during the third quarter.

DonCorleone77 Posted - 10/30/24

$BIO Bio-Rad reports Q3 EPS $2.01, consensus $1.16 Reports Q3 revenue $649.7M, consensus $628.17M. "Our third-quarter revenue performance was slightly ahead of expectations, driven by steady growth in clinical diagnostics products, while our life science business continued to improve reflecting a gradual recovery in the biopharma end market," said Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer. "During the quarter, we also welcomed Jon DiVincenzo as President and Chief Operating Officer. Jon joins Bio-Rad's other recently hired senior executives who collectively bring a wealth of life science, clinical diagnostics, and operations experience. With the new senior leadership team in place, we are focused on margin expansion, commercial excellence, and creating long-term shareholder value."

ChessGM Posted - 10/28/24

$BIO Upcoming Earnings Alert for 10/30/2024 Bearish (2.5) In the evaluation of Bio-Rad Laboratories (NYSE:BIO), the current sentiment reflects a challenging landscape for the company, particularly as it approaches its upcoming earnings report. The stock has experienced a significant decline of 58% over recent months, and the latest data indicates a further drop of 4.6% this past week. Analysts are projecting a decline in earnings, with concerns regarding the company's ability to meet expectations amidst ongoing weaknesses in the biotech and biopharma sectors. Key financial metrics such as the Price-to-Earnings (P/E) ratio, which currently stands above the industry average, coupled with stagnant earnings per share (EPS) growth, suggest that the stock may be overvalued in light of its performance. Revenue forecasts indicate a slowdown, and comparisons with industry peers further highlight the challenges faced by Bio-Rad in maintaining competitive growth rates. The strategic expansion of its digital droplet PCR (ddPCR) platform and a robust clinical diagnostics arm are positive aspects, yet they are overshadowed by the prevailing market sentiment and economic headwinds affecting the biotech sector. Looking ahead to the upcoming earnings report scheduled for October 30, 2024, expectations are tempered. Analysts consensus estimates indicate a significant year-over-year decline in both revenue and earnings, reflecting the impacts of market stagnation. Historically, Bio-Rad has shown volatility in its earnings performance, and this upcoming quarter is anticipated to be no different. The potential impact of the earnings results on the stock price could be pronounced, particularly if the outcomes fail to meet lowered expectations. Investors should be mindful of the market conditions and the company's strategic responses to these challenges as they position themselves for potential recovery or further decline in the stock's value. - Funds were net sellers of $BIO during the previous reporting quarter. - Top 1 funds with large holdings in $BIO: * Adage Capital P $5MM (Market Value). CGMFundScore: 86% - Last 10 days performance: -7% - Last 30 days performance: -3% - Last 90 days performance: -2% Follow ChessGM! Do not miss other earnings alerts from ChessGM. Not a financial advice.

Estimize Posted - 10/28/24

Wall St is expecting -0.62% YoY revenue growth for $BIO in Q3, up from -6.26% in Q2 [Reporting 10/30 AMC] http://www.estimize.com/intro/bio

jackedmund99 Posted - 10/24/24

$OCX so Biorad owns almost 9% of stock approx 1.510 mil shares and all we get is a yawn ? I believe BioRad $BIO is approx 330 per share 9 bill market cap doing biz with this little 42 mil market cap micro stock - yes I’ll buy more OCX thank you Mr market

swingingtech Posted - 10/24/24

$VLUE $EXE $BIO $NLY https://wallstreetwaves.com/unexpected-12-month-price-forecast-for-vlue-from-analysts/

swingingtech Posted - 10/23/24

$FTLF $BIO https://wallstreetwaves.com/fitlife-brands-ftlf-jumps-5-7-whats-next-for-the-stock/

Yann_Pro_Trader Posted - 1 month ago

$NKGN WATCH THIS !!! $NKGN 🚨🚨🚨🚨🚨🚨 $BURU $DRUG $BIO $JAGX

Aleouvet Posted - 1 month ago

$BIO 🚀:::;New alerts have been posted in the last hours..🚀 win-chat-market-live.trade-smartly.xyz

Shlobby Posted - 1 month ago

$BIO on the cusp of going big

WeeklyTrader Posted - 1 month ago

Let’s analyze what’s going wrong with $BIO! RSI: 56.3% 50-day MA: $328.89 200-day MA: $313.74

WeeklyTrader Posted - 1 month ago

Let’s chat about $BIO and its woes! RSI: 53.29% 50-day MA: $328.79 200-day MA: $313.65

WeeklyTrader Posted - 1 month ago

How are you feeling about the future of $BIO?

Shlobby Posted - 1 month ago

$BIO kind of slow. Setting up base. Above 345 will double up below 328 will cut.

Adamseb14 Posted - 1 month ago

$GLYC In the coming weeks, significant history in the studies. Great resilience everything turns out positive? Let not lose sight of it $BIO $LAB 🏆🏆🏆

Wigglyick Posted - 09/23/24

$BIO Road to Perdition or Yellow Brick Road ? Opinions are mixed. Will rate cuts help ?We’ll have to wait and see. Good luck.

Shlobby Posted - 2 months ago

$BIO setting up nicely here

DonCorleone77 Posted - 2 months ago

$ETSY $HVT $BIO $ERIE Etsy (ETSY) will replace Haverty Furniture Companies (HVT) in the S&P SmallCap 600. Bio-Rad Laboratories (BIO) will replace Erie Indemnity (ERIE) in the S&P MidCap 400 as part of the quarterly rebalancing.

SonGoku Posted - 2 months ago

Stocks being removed from S&P 500 $AAL $ETSY $BIO

kindness123 Posted - 2 months ago

$BIO $AAL $ETSY bye babes out $SPY $SPX 😅

cubie Posted - 2 months ago

@Pepper214 @SenecaAnalysis $nem $iff $tfc $bio all make money too

Alex_Hudson Posted - 08/28/24

$BIO RSI Cross Above Central Line With Good Volume.

ReversalToday Posted - 08/24/24

$BIO $NSC Reversal Today BIO PT 340 NSC PT 249

MoneyForFun_ Posted - 3 months ago

$BIO $SIGA Dead 🔥🩸💪

no1sbetter777 Posted - 3 months ago

$ATNM boooooom baby!!! . . . . . Maybe all of you should listen to me. Easy 30% gain $spy $nvda $bio